In last trading session, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) saw 1.25 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price level of $16.96 trading at $0.37 or 2.23% at ring of the bell on the day assigns it a market valuation of $2.23B. That closing price of CNTA’s stock is at a discount of -11.85% from its 52-week high price of $18.97 and is indicating a premium of 56.49% from its 52-week low price of $7.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.51 million shares which gives us an average trading volume of 593.83K if we extend that period to 3-months.
For Centessa Pharmaceuticals plc ADR (CNTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.35 in the current quarter.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Upright in the green during last session for gaining 2.23%, in the last five days CNTA remained trading in the green while hitting it’s week-highest on Wednesday, 01/29/25 when the stock touched $16.96 price level, adding 4.61% to its value on the day. Centessa Pharmaceuticals plc ADR’s shares saw a change of 1.25% in year-to-date performance and have moved 1.68% in past 5-day. Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) showed a performance of -1.74% in past 30-days. Number of shares sold short was 3.29 million shares which calculate 6.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 23 to the stock, which implies a rise of 26.26% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -12.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of -12.03% for stock’s current value.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
Statistics highlight that Centessa Pharmaceuticals plc ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company added 59.25% of value to its shares in past 6 months, showing an annual growth rate of -1.91% while that of industry is 17.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
In 2025, company’s earnings growth rate is likely to be around 2.97% while estimates for its earnings growth in next 5 years are of -3.20%.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
Insiders are in possession of 1.24% of company’s total shares while institution are holding 92.61 percent of that, with stock having share float percentage of 93.77%. Investors also watch the number of corporate investors in a company very closely, which is 92.61% institutions for Centessa Pharmaceuticals plc ADR that are currently holding shares of the company. MEDICXI VENTURES MANAGEMENT (JERSEY) LTD is the top institutional holder at CNTA for having 19.96 million shares of worth $180.27 million. And as of 2024-06-30, it was holding 19.9856 of the company’s outstanding shares.
The second largest institutional holder is GENERAL ATLANTIC, L.P., which was holding about 9.68 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6927 of outstanding shares, having a total worth of $87.43 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.98 shares of worth $50.48 million or 2.26% of the total outstanding shares. The later fund manager was in possession of 2.95 shares on Sep 30, 2024 , making its stake of worth around $49.98 million in the company or a holder of 2.24% of company’s stock.
